Viridian Therapeutics, Inc. filings document a clinical-stage biotechnology company with common stock listed on Nasdaq under VRDN. The company’s Form 8-K disclosures report financial results, Regulation FD clinical updates, corporate presentations, and material agreements, including underwriting arrangements for common stock offerings.
Viridian’s regulatory filings also cover its thyroid eye disease programs, including elegrobart trial disclosures and updates related to veligrotug, as well as cash resources, research and development activity, and financing transactions. Proxy materials document annual meeting matters, director elections, executive compensation, equity plans, and related governance procedures.
Viridian Therapeutics’ Chief Legal Officer Jennifer Tousignant reported multiple equity compensation transactions. On March 2, 2026, she received a grant of stock options for 119,300 shares and 23,850 restricted stock units, each RSU representing one share of common stock. The option grant vests in 48 equal monthly installments after the grant date, while the RSUs vest over four years, with 25% vesting on each yearly anniversary of the grant date, subject to continued service.
On March 3, 2026, 5,169 RSUs vested and were converted into 5,169 shares of common stock. In connection with this vesting, 1,724 shares of common stock were disposed of at $29.32 per share to cover tax withholding obligations. After these transactions, she directly held 15,510 RSUs and 3,445 shares of common stock.
Viridian Therapeutics Chief Financial Officer Seth Harmon reported multiple equity compensation moves. On March 2, 2026 he received a stock option covering 102,850 shares and 20,550 restricted stock units, each at a stated price of $0.00 per share. On March 3, 2026, 6,267 RSUs converted into common stock and 2,091 shares of common stock were withheld at $29.32 per share to cover taxes, leaving him with 7,790 common shares held directly.
Viridian Therapeutics’ Chief Financial Officer Seth Harmon filed an amended Form 4 to correct his reported share ownership. The amendment explains that a prior Form 4 filed on March 4, 2025 inadvertently omitted 1,711 shares purchased under the Viridian Therapeutics, Inc. 2016 Employee Stock Purchase Plan.
After reflecting these previously purchased shares, Harmon is shown as directly beneficially owning 1,711 shares of Viridian Therapeutics common stock. The filing does not report any new transactions, but updates the accuracy of his disclosed holdings.
Viridian Therapeutics, Inc. officer Jennifer Tousignant filed an amended Form 4 to correct her reported holdings. The prior filing inadvertently left out 610 shares that were purchased under the Viridian Therapeutics, Inc. 2016 Employee Stock Purchase Plan. After this correction, she is shown as directly owning 610 common shares.
Viridian Therapeutics Chief Operating Officer Thomas W. Beetham reported multiple equity award transactions. On March 2, 2026, he received a stock option grant for 176,550 shares vesting in 48 equal monthly installments, and 35,300 Restricted Stock Units (RSUs) vesting 25% annually over four years.
On March 3, 2026, 9,409 RSUs converted into the same number of common shares, and 3,138 common shares were disposed of at $29.32 per share to cover tax obligations. Following these transactions, he directly held 13,271 common shares and 28,227 RSUs.
Viridian Therapeutics President and CEO Stephen F. Mahoney reported multiple equity award transactions. On March 2, 2026, he was granted stock options for 559,600 shares that vest in 48 equal monthly installments after the grant date, and 111,900 restricted stock units (RSUs) that vest in four annual installments starting March 2, 2026.
On March 3, 2026, 18,357 RSUs converted into an equal number of common shares as part of a prior grant that vests annually from March 3, 2025. To cover tax obligations, 7,627 common shares were disposed of at $29.32 per share through tax withholding, leaving 33,130 common shares held directly.
Viridian Therapeutics Chief Medical Officer Radhika Tripuraneni reported equity awards consisting of stock options and restricted stock units. She acquired stock options for 95,800 shares at an exercise price of $0.00 per share, with the grant dated March 2, 2026. These options vest in 48 equal monthly installments, conditioned on continued service. She also received 19,150 restricted stock units, each representing one share of common stock. The RSUs vest over four years, with 25% vesting on each yearly anniversary of the March 2, 2026 grant date, also subject to continued service.
VRDN submitted a Form 144 reporting a proposed sale of 1,675 common shares described in the filing as related to Restricted Stock Vesting and Compensation.
The filing also lists a prior sale of 2,272 common shares dated 12/31/2025 with an indicated value of $70,795.52.